Roivant Sciences Ltd. (ROIV)
Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies. Its clinical product candidates include IMVT-1402, a fully human monoclonal antibody targeting FcRn in development across several IgG-mediated autoimmune indications; mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease; neonatal fragment crystallizable receptor for the treatment of graves' disease, difficult-to-treat rheumatoid arthritis, sjögren's disease, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and cutaneous lupus erythematosus indications; batoclimab, a fully human monoclonal antibody for the treatment of thyroid eye disease; and brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis, cutaneous sarcoidosis, and other immune-mediated diseases. The company's lead program consists of mosliciguat, an inhaled sGC activator for the treatment of pulmonary hypertension associated with interstitial lung disease and other cardiopulmonary diseases. In addition, the company offers delivery platforms comprising a lipid nanoparticle (LNP) platform and a ligand conjugate platform. Roivant Sciences Ltd. was founded in 2014 and is based in London, United Kingdom.
- Symbol
- ROIV
- Exchange
- Nasdaq
- Sector
- Healthcare
- Industry
- Biotechnology
- Market cap
- $27.62B
- 52 week range
- 14.5 - 42.5
Valuation
- Share price
- $36.82 (close of 2026-09-23)
- P/E (TTM)
- -106.17x
- Price to book
- 5.61x
- Price to free cash flow
- -33.64x
- Enterprise value
- $23.89B
- Book value per share
- $6.81
Price performance
| Period | Change |
|---|
| 1 day | -5.57% |
| 5 days | -6.78% |
| 1 month | +1.43% |
| 3 months | +14.31% |
| 6 months | +31.83% |
| Year to date | +69.68% |
| 1 year | +149.80% |
| 3 years | +256.44% |
| 5 years | +269.31% |
| All time | +254.04% |
Profitability and growth
- Return on equity
- -5.66%
- Return on invested capital
- -46.49%
- Return on assets
- -5.25%
- Return on capital employed
- -9.49%
- Net margin
- -3629.19%
- EBITDA margin
- -6195.16%
- Revenue growth
- -71.57%
- Net income growth
- -74.30%
- Free cash flow growth
- 10.13%
Cash flow and balance sheet
- Free cash flow yield (TTM)
- -2.97%
- Current ratio
- 16.72x
- Net debt to EBITDA
- 2.74x
Latest reported year
- Period end
- 2026-03-31
- Fiscal year
- 2026
- Revenue
- $8.26M
- EBITDA
- $-511.72M
- Net income
- $-299.77M
- Earnings per share
- $-0.43
- Research and development
- $681.81M
- Shares outstanding
- 693.86M
Income statement by year
| Period end | Revenue | Net income | EPS |
|---|
| 2026-03-31 | $8.26M | $-299.77M | $-0.43 |
| 2025-03-31 | $29.05M | $-171.98M | $-0.24 |
| 2024-03-31 | $32.71M | $4.35B | $5.55 |
| 2023-03-31 | $31.53M | $-1.01B | $-1.42 |
| 2022-03-31 | $55.29M | $-845.26M | $-1.26 |
| 2021-03-31 | $23.80M | $-809.23M | $-1.28 |
Margins and returns by year
| Period end | Net margin | Return on equity | Return on capital |
|---|
| 2026-03-31 | -3629.19% | -5.66% | -46.49% |
| 2025-03-31 | -591.96% | -3.32% | -250.52% |
| 2024-03-31 | 13294.18% | 67.44% | 59184.46% |
| 2023-03-31 | -3200.22% | -62.77% | -219.99% |
| 2022-03-31 | -1528.89% | -41.46% | -515.04% |
| 2021-03-31 | -3400.86% | -39.68% | -466.73% |
Cash and debt by year
| Period end | Cash | Debt |
|---|
| 2026-03-31 | $4.29B | - |
| 2025-03-31 | $4.89B | - |
| 2024-03-31 | $6.49B | $430.59M |
| 2023-03-31 | $1.68B | $375.51M |
| 2022-03-31 | $2.06B | $210.03M |
| 2021-03-31 | $2.06B | $170.28M |
Free cash flow by year
| Period end | Free cash flow | Stock-based compensation |
|---|
| 2026-03-31 | $-758.56M | $346.17M |
| 2025-03-31 | $-844.05M | $289.03M |
| 2024-03-31 | $-766.65M | $199.63M |
| 2023-03-31 | $-856.08M | $217.78M |
| 2022-03-31 | $-695.16M | $564.96M |
| 2021-03-31 | $-557.94M | $84.96M |
Investor relations
Next earnings report
- Next confirmed report
- 2026-11-09
Past earnings dates
| Reported | Fiscal period | EPS estimate |
|---|
| 2026-08-06 | Jun/2026 | - |
| 2026-05-20 | - | - |
| 2026-02-06 | - | - |
| 2025-11-10 | - | - |
| 2025-08-11 | - | - |
| 2025-05-29 | - | - |
| 2025-02-10 | - | - |
| 2024-11-12 | - | - |
Filings and sources
- Company website
- roivant.com
- SEC filings
- 10-K, 10-Q and 8-K on EDGAR
- Earnings calendar
- All upcoming reports
Similar companies
Vertex Pharmaceuticals Inc (VRTX) · Regeneron Pharmaceuticals, Inc. (REGN) · Moderna, Inc. (MRNA) · Incyte Corp (INCY) · Bio-Techne Corp (TECH) · Thermo Fisher Scientific Inc. (TMO) · Danaher Corp (DHR) · IQVIA Holdings Inc. (IQV)
All Healthcare companies
Understanding these figures
Price-to-earnings ratio · Discounted cash flow · Free cash flow · Earnings per share · Return on equity · Gross margin vs net margin · Reading a balance sheet · Debt and leverage · Dividend yield · Insider transactions and Form 4 · How to read a stock chart
Explore
Company directory · S&P 500 heatmap · Earnings calendar · Super investor holdings · Congress trades